Fenofibric acid (FA) is a class II biopharmaceutical system drug, a potential drug forantihyperlipidemic. FA lowers low-density lipoprotein (LDL) and triglyceride levels andincreases high-density lipoprotein (HDL). Due to its low solubility, the bioavailability of FA isalso low. To overcome the undesirable effects of these biopharmaceutical properties, this studyfocused on improving the solubility of FA in the form of FA multicomponent crystals withtheobromine (TH) coformer using solvent drop grinding as the crystallisation method.Multicomponent crystals of FA with TH coformer named FA-TH were successfully prepared.Detailed structural studies of this new solid form were carried out using powder X-ray diffraction(PXRD), Fourier Transform Infrared (FT-IR), Differential Scanning Calorimetry (DSC),Scanning Electron Microscope (SEM), and hot-stage microscopy. The thermogram of the DSCtest showed that the melting point of FA-TH multicomponent crystals was lower than the meltingpoint of the forming compound. The X-ray diffraction exhibits diffraction peaks of FA-THmulticomponent crystal and superimposition between the diffraction peaks of FA and TH.Solubility of FA-TH multicomponent crystals showed improvement up 4.4-fold compared to pureFA. These results demonstrate the potential of this new solid form to improve the solubility of FA.
No takes yet. Share an insight, caveat, or question.
Anggraini et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: